Research graph
References from Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL. Local targets link to admitted publications; unresolved targets remain external evidence.
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
10.1038/s41591-024-02986-9 · 2024 · External reference
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
10.1016/s1470-2045(21)00591-x · 2022 · External reference
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
10.1038/s41591-021-01622-0 · 2022 · External reference
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
10.1016/s1470-2045(22)00335-7 · 2022 · External reference
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
10.1016/s2352-3026(24)00166-2 · 2024 · External reference
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma
10.1016/j.annonc.2024.08.2239 · 2024 · External reference
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
10.1016/s0140-6736(20)31366-0 · 2020 · External reference
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
10.1182/blood.2022018730 · 2023 · External reference
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
10.1016/s1470-2045(22)00339-4 · 2022 · External reference
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study
10.1016/s0140-6736(23)01052-8 · 2023 · External reference
Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study
10.1200/jco.23.02214 · 2024 · External reference
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study
10.1016/s0140-6736(25)02435-3 · 2026 · External reference
Unresolved reference
2024 · External reference
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
10.1200/jco.2013.54.8800 · 2014 · External reference
Unresolved reference
External reference
An empirical transition matrix for non-homogeneous Markov chains based on censored observations
1978 · External reference
Unresolved reference
2006 · External reference
Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): TRANSCEND FL 2-year follow-up [abstract]
10.1182/blood-2024-198509 · 2024 · External reference
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
10.1182/blood.2023021243 · 2024 · External reference
Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 ELARA 3-year follow-up [abstract]
10.1182/blood-2023-180936 · 2023 · External reference
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
10.1182/blood.2023021567 · 2024 · External reference
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
10.1182/blood.2024025454 · 2025 · External reference
Long-term efficacy and survival outcomes with odronextamab for patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): 2-year follow-up from the phase 2 ELM-2 study
2025 · External reference
Epcoritamab monotherapy demonstrates deep and durable responses at 3-year follow-up in patients with relapsed/refractory follicular lymphoma
2025 · External reference
Mosunetuzumab demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated R/R FL after ≥3 years of follow-up: subgroup analysis of a pivotal phase II study
2024 · External reference
Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018
10.1038/s41408-021-00574-5 · 2021 · External reference
Risk of second primary malignancies in patients with follicular lymphoma: a United States population-based study
10.1016/j.clml.2017.06.028 · 2017 · External reference
Optimizing post–chimeric antigen receptor (CAR) T cell monitoring: evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience
10.1200/jco.2025.43.16_suppl.7026 · 2025 · External reference
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL
10.1182/bloodadvances.2024013254 · 2024 · External reference
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel
10.1182/bloodadvances.2023012549 · 2024 · External reference
Unresolved reference
External reference
Efficacy and safety of long-term odronextamab treatment in patients with relapsed/refractory follicular lymphoma: 3-year follow-up from the Phase 2 ELM-2 study [abstract]
10.1182/blood-2025-3588 · 2025 · External reference
